Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry

Academic source · mAbs

Source published: · Event / reporting date: 2026-07-15

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What the paper reports

This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.

Why this paper is included

Useful when deciding which characterization questions justify a native-MS workflow.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Biologics Characterization & CMC Analytics

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

PharmaronCharles River LaboratoriesSelvitaNuvisanEurofins Discovery
Explore field companies →Explore literature →

Related updates

Communications Chemistry

Direct-infusion method accelerates antibody peptide mapping in a peer-reviewed study

A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.

Biologics Characterization & CMC AnalyticsAsk AI ↗
U.S. Food and Drug Administration

FDA finalizes lifecycle potency assurance guidance for cell and gene therapies

FDA announced final guidance on potency assurance for cellular and gene therapies on November 2. Its recommendations integrate manufacturing-process design, material and process controls, in-process testing, and lot-release potency assays. The agency emphasizes product-specific, risk-based strategies across development and commercialization; this is final guidance, not approval of any individual therapy.

Biologics Characterization & CMC Analytics In Vivo Cell Engineering & Gene EditingAsk AI ↗
BioAgilytix

BioAgilytix reports progress following its GMP analytical expansion

BioAgilytix reviewed its earlier analytical investment in Morrisville and Hamburg, describing infrastructure for GMP QC, characterization, bioassays, release, and stability programs. This is a May 2026 company update about previously expanded capabilities, not a newly announced November facility opening or independent quality certification.

Companies mentionedBioAgilytix ↗
Biologics Characterization & CMC AnalyticsAsk AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗